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CHEMOTHERAPY OF TUBERCULOUS MENINGITIS WITH ISONIAZID
PLUS RIFAMPICIN–INTERIM FINDINGS IN A TRIAL IN CHILDREN*
PADMA RAMACHANDRAN
Summary: Seventy six cases of tuberculous meningitis admitted to the Institute of Child Health and
Hospital for Children, Madras were treated with a regimen of rifampicin, isoniazid and streptomycin
daily for two months, followed by streptomycin twice a week plus ethambutol and isoniazid daily
for 4 months. Treatment with isoniazid and ethambutol daily was continued for a further period of
6 months. In the earlier part of the study. isoniazid was prescribed in a dosage of 20 mg/kg.It was
noted that about half of the children on isoniazid 20 mg/kg developed clinical jaundice with elevated
levels of serum bilirubin and SGOT and SGPT levels. It was considered likely that the ‘high dosage
of isoniazid might have contributed to the high incidence ofjaundice and hence the dosage of thesame
was reduced to 12 mg/kg. With the reduced dosage of isoniazid, the incidence of jaundice wasmuch
lower, namely 20 %. 54 patients have so far completed the treatment period of 1 year. 13 of thesedied
after admission to the study. The clinical and laboratory findings are presented.
Amongst all forms of tuberculosis, tuber-
culous meningitis still carries a high mortality
and morbidity. This is due to the lack of estab-
lished diagnostic criteria in the absence of
bacteriological evidence and also because of the
prolonged nature of therapy leading to irregular
and incomplete treatment in the later months of
chemotherapy.
Materials & Methods
76 cases of TB meningitis aged between 1 and
12 years who had not received more than
tw  w eks of previous anti-tuberculosis treat-
ment were admitted to the study.
Criteria for diagnosis:
The advent of the bactericidal drug rifampicin
and the re-entry of pyrazinamide in the field of
chemotherapy have dramatically changed the
prospects of developing regimens which produce
sterilisation of tuberculous lesions and have
helped in reducing the duration of chemotherapy
of pulmonary tuberculosis from the conventional
12-18 months to about 6 months. Rifampicin
has been found to enhance the efficacy of regi-
mens even when given only for the first two
months The combination of rifampicin plus
isoniazid has also been found to be highly effec-
tive in the treatment of tuberculosis of the
spine in Madras patients. Information on the
value of rifampicin in the chemotherapy of
tuberculous meningitis is limited. The high effi-
cacy of rifampicin-regimens in pulmonary tuber-
culosis and tuberculosis of the spine suggests
that rifampicin-containing regimens would be
of great value in the treatment of tuberculous
meningitis. The interim findings of a study which
is being undertaken to investigate the efficacy
of a rifampicin-containing regimen in tuber-
culous meningitis in children in Madras are
presented in this paper.
Cli ical : Presence of signs like fever, vomit-
ing,irritability, apathy, refusal to play, anorexia
and constipation in the early stages followed by
well marked meningeal signs, mental confusion,
neurological signs, coma and widespread paraly-
sis.
CSF Changes :
Pr tein content more than 40 mgs %.
Sugar Content less than 50 mgs % .
Cells more than 10/cmm. predominantly
lymphocytes.
Investigation
Th  following investigations were carried
out :
1. Mantoux test: A 1 TU Mantoux test
(PPD batch RT 23 with tween 80) on admission.
2. X-Ray Chest on admission and at the end
of treatment.
The study is being conducted by the Tuber-
culosis Research Centre of the Indian Council
of Medical Research in collaboration with the
Institute of Child Health and Hospital for
Children, Madras, from where the patients are
drawn.
3. Routine urine analysis and tests for
acetyl isoniazid, bile salts, bile pigments and
urobilinogen every month.
4. Estimations of SGOT, SGPT activity,
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serum bilirubin, blood Urea and Creatinine an
admission, at 1 and 2 months and at the end of
months. During the first 2 months, the patients
chemotherapy.
w re treated with 3 drugs-streptomycin, isoniazid
and rifampicin daily (Table 2). During 3-6
5. Estimation of haemoglobin, blood platelet
months, they received ethambutol plus isoniazid
count, total and differential white blood cell
daily, supplemented by streptomycin admini-
counts on admission, at 1 and 2 months and at
ster d twice a week. During the last 6 months,
they were treated with ethambutol plus isoniazid
the end of chemotherapy. daily.
6. CSF examination for biochemical, cyto- Table 2
logical, smear and bacteriological examinations Drug Regimens
on admission and every two weeks thereafter.
Staging on admission : Month Drugs
At the time of admission patients were
examined in detail with special reference to
nervous system. They were classified into 3
stages (Table I) according to the British Medical
0-2
3-6
Streptomycin, isoniazid and rifampicin daily.
Ethambutol and isoniazid daily plus strepto-
mycin twice-weekly.
Table 1
7-12 Ethambutol and isoniazid daily.
Staging on Admission
Stage
Patients
No. %
I 9 12
II 62 82
III 5 6
Total 76 100
Streptomycin was employed in a dosage of
40 mg/kg body-weight, rifampicin 12 mg/kg
daily and ethambutol 17.5 mg/kg daily (Table-3).
The first 26 patients were treated with isoniazid
in a daily dosage of 20 mg/kg, a dosage common-
ly used by most Indian paediatricians for the
treatment of tuberculous meningitis. However, a
large number of them developed clinical jaun-
dice during the initial phase of treatment with
isoniazid and rifampicin. It was considered
likely that the high dosage of isoniazid might
have contributed to the high incidence of hepa-
to-toxicity. Patients admitted to the study subse-
quently were all treated with a lower dose
namely, 12 mg/kg isoniazid.
Research Council (1948) classification. Cases
Table 3
were divided into :
Drugs and dosages
Stage I : Patients were fully conscious and
rational with signs of meningeal irritation but
with no focal neurological signs or signs of
hydrocephalus.
Streptomycin
Rifampicin
Stage II: Patients were mentally confused
and/or had such neurological signs as squints or
hemiparesis.
Ethambutol
Isoniazid
Stage III : Patients were mentally inaccessible
owing to the depth of stupor or delirium on
admission and/or had a complete hemiplegia orResults
40 mg/kg.
12 mg/kg.
17.5 mg/kg.
20 mg/kg (26 pts.)
12 mg/kg (50 pts)
paraplegia. Characteristics on admission:
Treatment Schedules: All the patients in the study were under 7
years of age, and 88% were aged 4 years or less
All patients were treated for a period of 12(Table 4).
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Table 4 Table 5
Age distribution Mantoux results
PADMA RAMACHANDRAN
Age
(years)
Patients
1
2
3
4
5
6
7–12
Total
26 34%
15 20%
11 14%
15 20%
5 7%
4 5%
0 0
76
Tuberculin test was positive with indurations
of 10 mm or more in about half of the patients
(Table 5). The remaining patients had reactions
of less than 10 mm( including a third (34%) who
had a reaction of ‘0’ mm. Cerebrospinal fluid
was positive for Mycobacterium tuberculosis in
30% of the cases (Table 6). Thirty four (45%)
patients had a history of contact with pulmonary
tuberculosis and 38 (50%) had an abnormal
chest X-ray suggestive of pulmonary tubercu-
losis.
Clinical Progress :
Of the 76 patients, 54 have completed 1 year
of treatment. Of these, 13 (24%) patients died
after admission to the study, 20 (37%) patients
made a complete recovery and the remaining
21 (39%) patients also recovered but had been
left with residual damage, which was considered
to be severe in 15% and mild to moderate in
24% (Table 7). Mild residual damage implied
such sequelae as hyperactivity, irritability, mild
perceptual defects and slight motor impairment
like facial paresis or monoparesis. Moderate
residual damage included such defects as hemi-
paresis, involuntary movements and mental
dullness. Severely damaged children usually
remained unconscious or if consciousness was
regained they were incapable of independent
life.
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Induration
(mm)
0
1-4
5-9
10-14
15-19
20-29
N.A.
Total
Table 6
Stage
Patients
Bacteriological findings onadmission
I 9 12%
II 62 82%
III 5 6%
26 34%
10 13%
3 4%
13 17%
16 21%
7 9%
1 1%
76
Patients
Total 76 23 (30%)
Culture
Positive
4
18
1
Hepatotoxicity:
As pointed out earlier the first 26 cases were
given isoniazid in a dosage of 20 mg/kg daily.
Four cases died before completing the rifampicin
therapy (Table 8) ; they did not have hepatic
toxicity and are excluded from the analysis.
Out of the remaining 22 cases, 11 (50%) deve-
loped clinical jaundice with elevated serum
bilirubin levels and a significant rise in the
SGOT and SGPT levels. The treatment in these
cases was suitably modified.
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Table7
Status at 1 year
Stage
I
II
III
All
No. of patients
7
45
2
54
Deaths
0
11
2
Residual damage
Severe Mod/Mild
1 0
7 13
0 0
Table 8
Incidence of Jaundice in the first two months
No. of patients
Deaths
No. in analysis
Developed Jaundice
High Dose Low Dose
INH 20 mg/kg INH 12 mg/kg
26 50
4 10
22 40
11 (50%) 8 (20 %)
Complete
recovery
6
14
0
and none of them had hepatic toxicity. Out of
the remaining 40 cases, 8 developed jaundice
with elevated bilirubin, SGOT and SGPT levels.
Thus there was a reduction in the incidence of
jaundice following reduction of the dosage of
isoniazid, but the incidence is still high. This
suggests that the use of a combination of isonia-
zid plus rifampicin entails a high risk of hepato-
toxicity in children with tuberculous meningitis.
Conclusions
It was considered likely that the high dosage
of isoniazid (20 mg/kg) when given in combina-
tion with rifampicin may have contributed to
the high incidence of jaundice. The daily dosage
of isoniazid was, therefore, reduced to 12 mg/kg
in the subsequent part of the study. Fifty patients
were treated with the regimen containing the
lower dosage of isoniazid. Ten patients died
before completing the two months of treatment
In conclusion, the combination of isoniazid
20 mg/kg plus rifampicin administered daily,
was associated with high and unacceptable
levels of hepatotoxicity in children with tuber-
culous meningitis; the incidence was substantial-
ly lower in children treated with a lower dosage
of isoniazid, namely 12 mg/kg, plus rifampicin.
The r sults of chemotherapy with a regimen of
isoni zid plus rifampicin daily for 2 months,
followed by ethambutol plus isoniazid daily
for 10 months, supplemented with streptomycin
during the first 6 months were highly encouraging.
Thus, as many as 76% of the patients had
surviv d at the end of one year, a gratifying
finding considering that over 80% of the patients
belonged to stage II or stage III on admission.
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